Literature DB >> 6597118

Reversal of multidrug resistance by non-antitumor anthracycline analogs.

M Inaba, K Nagashima, Y Sakurai, M Fukui, Y Yanagi.   

Abstract

It was found that three synthetic anthracycline analogs lacking not only antitumor activity but also calcium-antagonizing action possessed an activity to potentiate vincristine cytotoxicity against vincristine-resistant P388 leukemia. ID-8279, one of these analogs, significantly reversed resistance to vincristine and daunorubicin by increasing their intracellular accumulation.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6597118

Source DB:  PubMed          Journal:  Gan        ISSN： 0016-450X


  7 in total

1.  Monitoring the chemosensitizing effects of toremifene with flow cytometry in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  W J Baker; V J Wiebe; S K Koester; V D Emshoff; J U Maenpaa; G T Wurz; M W DeGregorio
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  A phase II study of intensive-dose epirubicin/verapamil as induction therapy followed by intensive-dose ifosfamide for advanced breast cancer.

Authors:  T Langenbuch; K Mross; W Jonat; D K Hossfeld
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

3.  Saturable process involved in active efflux of vincristine as a mechanism of multidrug resistance in P388 leukemia cells.

Authors:  T Watanabe; M Inaba; Y Sugiyama
Journal:  Pharm Res       Date:  1989-08       Impact factor: 4.200

4.  Toremifene and its metabolites enhance doxorubicin accumulation in estrogen receptor negative multidrug resistant human breast cancer cells.

Authors:  V Wiebe; S Koester; M Lindberg; V Emshoff; J Baker; G Wurz; M DeGregorio
Journal:  Invest New Drugs       Date:  1992-07       Impact factor: 3.850

5.  Modulation of drug cytotoxicity in wild-type and multidrug-resistant tumor cells by stereoisomeric series of C-20'-vinblastine congeners that lack antimicrotubule activity.

Authors:  L S Borman; W G Bornmann; M E Kuehne
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

6.  Targeting chemosensitizing doses of toremifene based on protein binding.

Authors:  G T Wurz; V D Emshoff; M W DeGregorio; V J Wiebe
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Pharmacologic circumvention of multidrug resistance.

Authors:  J M Ford; W N Hait
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.